Literature DB >> 8163720

Drug dosing in renal insufficiency.

R L Talbert1.   

Abstract

Drug dosing in renal insufficiency needs to be individualized whenever possible to optimize therapeutic outcomes and to minimize toxicity. Although a number of published tables that provide dosing guidelines and nomograms exist to assist in dose modification, individualization of therapy should be based on pharmacokinetic principles whenever possible. The basis equations to estimate the pharmacokinetic parameters of clearance, volume of distribution, and half-life for intravenous drug administration of drugs with first-order kinetics are not difficult to understand and apply. Their use should be encouraged in patient care.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163720     DOI: 10.1002/j.1552-4604.1994.tb03973.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  18 in total

Review 1.  Nephrology: 3. Safe drug prescribing for patients with renal insufficiency.

Authors:  Joanne Kappel; Piera Calissi
Journal:  CMAJ       Date:  2002-02-19       Impact factor: 8.262

2.  Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.

Authors:  S Mallikaarjun; W P Forbes; S L Bramer
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

3.  Renal elimination of organic anions in cholestasis.

Authors:  Adriana Monica Torres
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

4.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

Review 5.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

Review 6.  A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.

Authors:  Thomas D Nolin
Journal:  Semin Dial       Date:  2015-04-08       Impact factor: 3.455

7.  Alterations of Hepatic Metabolism in Chronic Kidney Disease via D-box-binding Protein Aggravate the Renal Dysfunction.

Authors:  Kengo Hamamura; Naoya Matsunaga; Eriko Ikeda; Hideaki Kondo; Hisako Ikeyama; Kazutaka Tokushige; Kazufumi Itcho; Yoko Furuichi; Yuya Yoshida; Masaki Matsuda; Kaori Yasuda; Atsushi Doi; Yoshifumi Yokota; Toshiaki Amamoto; Hironori Aramaki; Yasuhiro Irino; Satoru Koyanagi; Shigehiro Ohdo
Journal:  J Biol Chem       Date:  2016-01-04       Impact factor: 5.157

8.  Renal elimination of amikacin and the aging process.

Authors:  M Ducher; P Maire; C Cerutti; Y Bourhis; F Foltz; P Sorensen; R Jelliffe; J P Fauvel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 9.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 10.  The effect of chronic renal failure on drug metabolism and transport.

Authors:  Albert W Dreisbach; Juan J L Lertora
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-08       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.